HIV/AIDS Clinical Trials

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

Condition: Immune Reconstitution Inflammatory Syndrome; HIV; HIV Infections

NCT ID: NCT00988780

Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

Condition: HIV; HIV Infections

NCT ID: NCT00966329

Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration

Condition: HIV Infection; HIV Infections

NCT ID: NCT00944541

Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1

Condition: HIV-1 Infection; HIV Infections

NCT ID: NCT00993148

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Condition: Human Immunodeficiency Virus (HIV)

NCT ID: NCT00791700

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine

Condition: HIV Infections

NCT ID: NCT00808002

Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

Condition: HIV Infections

NCT ID: NCT00987948

Effect of Maraviroc on Endothelial Function in HIV-Infected Patients

Condition: HIV Infection; Cardiovascular Disease; Inflammation; HIV Infections

NCT ID: NCT00844519

Maraviroc in Immunological Non-Responder (INR) HIV-1-infected Subjects

Condition: HIV Infections

NCT ID: NCT00884858

First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers

Condition: HIV

NCT ID: NCT01719627

R5 Integrase Study in HIV-1 Naive Patients

Condition: HIV Infections

NCT ID: NCT01204905

Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens

Condition: HIV Infections

NCT ID: NCT01049204

Terminated

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

Condition: HIV Infection

NCT ID: NCT00735072

Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

Condition: HIV

NCT ID: NCT00634959

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in Men Who Have Sex With Men and in At-Risk Women

Condition: HIV Infection

NCT ID: NCT01505114

Recruiting(En español)

Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients

Condition: HIV-1 Infection; AIDS

NCT ID: NCT01348308

Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir

Condition: HIV Infections; Treatment Experienced

NCT ID: NCT00976404

Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)

Condition: HIV Infection

NCT ID: NCT01533272

New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients

Condition: HIV Infections

NCT ID: NCT00908544

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

Condition: HIV Infections

NCT ID: NCT00525733

Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3

Condition: HIV-1 Infection

NCT ID: NCT01235013

Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

Condition: HIV Infections

NCT ID: NCT00643643

Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers

Condition: HIV Infections

NCT ID: NCT00771823

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Condition: Human Immunodeficiency Virus-1

NCT ID: NCT00827112

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

Condition: HIV Infections

NCT ID: NCT00098722

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

Condition: HIV Infections

NCT ID: NCT00098748

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

Condition: HIV Infections; Acquired Immunodeficiency Syndrome

NCT ID: NCT00981318

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

Condition: HIV Infections

NCT ID: NCT00098306

Double-method Comparative Study in Order to Predict the Use of Co-receptors From Type 1 HIV: Phenotypic Study (Trofile ESTA®) and Virologic Response to a CCR5 Antagonist in the Short Term

Condition: HIV Infections

NCT ID: NCT01060618

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

Condition: HIV-1 Infections

NCT ID: NCT01033760

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Condition: Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic

NCT ID: NCT00782301

Withdrawn

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With Ccr5 Tropic HIV 1

Condition: HIV-1

NCT ID: NCT01345630

Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women

Condition: HIV

NCT ID: NCT01749566

Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients

Condition: HIV

NCT ID: NCT01291459

MARCH Central Nervous System Substudy

Condition: HIV-1 Infection

NCT ID: NCT01637233

CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

Condition: HIV Infections

NCT ID: NCT00925756

The St. Marys and The Mater Switch Study

Condition: HIV Infections

NCT ID: NCT00981773

Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1

Condition: HIV-1

NCT ID: NCT00795444

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

Condition: HIV Coinfection; Hepatitis C; Hepatitis B; Hepatotoxicity

NCT ID: NCT01327547

Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection

Condition: HIV-1

NCT ID: NCT00850395

Multicenter, Safety Study Of Maraviroc

Condition: Acquired Immunodeficiency Syndrome; HIV Infection

NCT ID: NCT00478231

Genotypic Tropism Testing In Proviral Dna To Guide CCR5 Antagonist Treatment In Subjects With Undetectable HIV-1 Viremia

Condition: HIV

NCT ID: NCT01378910

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients

Condition: HIV-1 Adults Patients; AIDS; Triple Class Failure

NCT ID: NCT01013987

Intense Acute Infection Study

Condition: Acute HIV Infection

NCT ID: NCT01154673

A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India

Condition: Human Immunodeficiency Virus (HIV)

NCT ID: NCT00992654

No longer available

Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers

Condition: Human Immunodeficiency Virus (HIV) Infection

NCT ID: NCT00821535

Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function

Condition: Human Immunodeficiency Virus (HIV) Infection

NCT ID: NCT00717067

IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients

Condition: HIV Infections

NCT ID: NCT00935480

The Maraviroc Central Nervous System (CNS) Study

Condition: HIV Infections

NCT ID: NCT00982878

A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium

Condition: HIV Infections

NCT ID: NCT01242579

Withdrawn

Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia

Condition: HIV

NCT ID: NCT01275625

Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy

Condition: Human Immunodeficiency Virus; Lipohypertrophy

NCT ID: NCT01420523

EuroSIDA As An External Comparator To MOTIVATE Trials

Condition: HIV; AIDS

NCT ID: NCT01329783

Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc/Lamivudine

Condition: HIV; Impaired Cognition

NCT ID: NCT01367236

Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)

Condition: CCR5-tropic HIV-1 Infection

NCT ID: NCT00864474

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Condition: Human Immunodeficiency Virus

NCT ID: NCT00665561

Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring

Condition: HIV Infections

NCT ID: NCT01363037

A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy

Condition: HIV Infections

NCT ID: NCT00870363

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

Condition: HIV-1 Infection

NCT ID: NCT01400412

Effect Of Maraviroc On The Pharmacokinetics Of Digoxin

Condition: Healthy; HIV Infections

NCT ID: NCT01056874

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)

Condition: HIV Infections

NCT ID: NCT01068873

Switch to Darunavir/r + Maraviroc QD in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)

Condition: HIV Infection

NCT ID: NCT01367210

Maraviroc Immune Recovery Study

Condition: HIV Infections

NCT ID: NCT00875368

Expanded Access Program for Maraviroc At Multiple Centers

Condition: Advanced HIV Infection

NCT ID: NCT00426660

Maraviroc Switch Collaborative Study

Condition: HIV

NCT ID: NCT01384682

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

Condition: HIV-1

NCT ID: NCT00098293

Active, not recruiting(En español)

Optimizing Treatment for Treatment-Experienced, HIV-infected People

Condition: HIV Infections

NCT ID: NCT00537394

PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen

Condition: HIV Infection

NCT ID: NCT01190293

Safety Study of Maraviroc's Effect on Human Osteoclasts

Condition: HIV Infections; AIDS

NCT ID: NCT01428986

Enrolling by invitation

Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression

Condition: HIV Infections

NCT ID: NCT00709111

Completed(En español)

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

Condition: HIV Infections

NCT ID: NCT00703586

Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Condition: HIV Infections

NCT ID: NCT00977756

The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study

Condition: HIV

NCT ID: NCT01348763

Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay

Condition: HIV Infections

NCT ID: NCT00496782

Terminated

Sex, Aging and Antiretroviral Pharmacokinetics

Condition: HIV Infections

NCT ID: NCT00666055

A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™

Condition: Infection, Human Immunodeficiency Virus I

NCT ID: NCT01597648

An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01776996

MARCH Renal Substudy

Condition: Proteinuria; HIV

NCT ID: NCT01637259

A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

Condition: HIV

NCT ID: NCT00801515

No longer available

Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients

Condition: HIV-1 Infection

NCT ID: NCT01019551

Maraviroc Compassionate Use

Condition: Human Immunodeficiency Virus Type 1

NCT ID: NCT00719823

Withdrawn

Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects

Condition: Birth Defects; Infection, Human Immunodeficiency Virus

NCT ID: NCT01137981

Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection

Condition: HIV Infections; Hepatitis C

NCT ID: NCT00879047

A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study

Condition: HIV

NCT ID: NCT01680536

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

Condition: Kaposi's Sarcoma

NCT ID: NCT01276236

Enrolling by invitation

Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue

Condition: HIV/AIDS

NCT ID: NCT00775294

Antiretroviral Therapy for Acute HIV Infection

Condition: Acute HIV Infection

NCT ID: NCT00796263

Clinical Trial of CNS-targeted HAART (CIT2)

Condition: HIV Infections

NCT ID: NCT00624195

Concentrations of Maraviroc in the Semen of HIV-Infected Men

Condition: Maraviroc Concentrations in Semen

NCT ID: NCT01009034

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Condition: HIV Infections

NCT ID: NCT00042289

Recruiting(En español)

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Condition: Healthy

NCT ID: NCT01290211

The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers

Condition: Healthy

NCT ID: NCT01627717

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Condition: Healthy

NCT ID: NCT01140412

Terminated

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

Condition: Healthy

NCT ID: NCT01597895